Related references
Note: Only part of the references are listed.Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic
Satyajit Tripathy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Eli S. Rosenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Prescribing COVID-19 treatments: what we should never forget
S. Tunesi et al.
JOURNAL OF INFECTION (2020)
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Wei Tang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Virological assessment of hospitalized patients with COVID-2019
Roman Woelfel et al.
NATURE (2020)
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Jia Liu et al.
CELL DISCOVERY (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Gian Marco Casillo et al.
PHARMACOLOGICAL RESEARCH (2020)
Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus
Ji Yang et al.
JOURNAL OF RHEUMATOLOGY (2018)
Share Paper
